Merus Reveals Interim Results for Bispecific Antibody Petosemtamab with Pembrolizumab at 2024 American Society of Clinical Oncology Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
Merus N.V. (NASDAQ:MRUS) announced interim clinical data from its phase 1/2 trial of the bispecific antibody petosemtamab in combination with pembrolizumab. The data will be presented at the 2024 ASCO Annual Meeting.
May 28, 2024 | 11:08 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Merus N.V. announced promising interim clinical data for its bispecific antibody petosemtamab in combination with pembrolizumab. The data will be presented at the 2024 ASCO Annual Meeting, potentially boosting investor confidence.
The announcement of promising interim clinical data and the upcoming presentation at a prestigious conference like ASCO can generate positive sentiment among investors, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100